|
But, Dr. Force and colleagues reported today in the online issue of
Nature Medicine, 10 CML patients treated with Gleevec at the M.D. Anderson
Cancer Center in Houston developed congestive heart failure, although they
had normal heart function
when they began taking the drug. Studies in mice and in culture showed that the
Abl tyrosine kinase protects cardiac cells from damage; when it is inhibited, heart cells die. Dr. Force and colleagues called cardiotoxicity "an unanticipated side effect"
of Gleevec. However, they
provided no indication of what they suspected the rate of congestive heart failure might
be. "Clinical trials of the agent, however, have reported a relatively high
incidence of peripheral edema (63% to 66%), some of which has been classified as
severe (4% to 5%)," they wrote. "In addition, dyspnea has been reported in 12%
to 16% of treated individuals and has been classified as severe in 4% to 5%."
"Although these symptoms and signs are difficult to evaluate in individuals
with CML, it has become apparent to us in clinical practice that many
individuals, including those reported herein, have developed left ventricular
dysfunction and even frank congestive heart failure without a
prior history of heart
disease." They characterized Gleevec as a "wonderful drug
and patients with these diseases need to be on it." Nevertheless, "we're trying
to call attention to the fact that Gleevec and other similar
drugs coming along could have significant side effects on the heart and clinicians need to
be aware of this." The researchers recommended that patients taking --~--~---------~--~----~------------~-------~--~----~ [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group.
|

